<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>American Joint Committee on Cancer TNM staging system for cutaneous squamous cell carcinoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">American Joint Committee on Cancer TNM staging system for cutaneous squamous cell carcinoma</h1>
<div class="graphic"><div class="figure"><div class="ttl">American Joint Committee on Cancer TNM staging system for cutaneous squamous cell carcinoma</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single" colspan="4">Primary tumor (T)<sup>*</sup></td> </tr> <tr> <td>TX</td> <td colspan="3">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td colspan="3">No evidence of primary tumor</td> </tr> <tr> <td>Tis</td> <td colspan="3">Carcinoma in situ</td> </tr> <tr> <td>T1</td> <td colspan="3">Tumor 2 cm or less in greatest dimension with less than two high-risk features (see list of high-risk features below)</td> </tr> <tr> <td rowspan="2">T2 </td> <td colspan="3">Tumor greater than 2 cm in greatest dimension <strong>OR</strong></td> </tr> <tr> <td colspan="3">Tumor any size with two or more high-risk features</td> </tr> <tr> <td>T3</td> <td colspan="3">Tumor with invasion of maxilla, mandible, orbit, or temporal bone</td> </tr> <tr> <td>T4</td> <td colspan="3">Tumor with invasion of skeleton (axial or appendicular) or perineural invasion of skull base</td> </tr> <tr> <td class="subtitle2_left" colspan="4">High-risk features for the primary tumor (T) staging</td> </tr> <tr> <td class="indent1" rowspan="3">Depth/invasion</td> <td colspan="3">&gt;2 mm thickness</td> </tr> <tr> <td colspan="3">Clark level ≥IV</td> </tr> <tr> <td colspan="3">Perineural invasion</td> </tr> <tr> <td class="indent1" rowspan="2">Anatomic location</td> <td colspan="3">Primary site ear</td> </tr> <tr> <td colspan="3">Primary site hair-bearing lip</td> </tr> <tr> <td class="indent1">Differentiation</td> <td colspan="3">Poorly differentiated or undifferentiated</td> </tr> <tr> <td class="subtitle1_single" colspan="4">Regional lymph nodes (N)</td> </tr> <tr> <td>NX</td> <td colspan="3">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td>N0</td> <td colspan="3">No regional lymph node metastases</td> </tr> <tr> <td>N1</td> <td colspan="3">Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension</td> </tr> <tr> <td class="sublist1_start">N2</td> <td class="sublist_other_start" colspan="3">Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension</td> </tr> <tr> <td class="sublist1">N2a</td> <td class="sublist_other" colspan="3">Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension</td> </tr> <tr> <td class="sublist1">N2b</td> <td class="sublist_other" colspan="3">Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension</td> </tr> <tr> <td class="sublist1">N2c</td> <td class="sublist_other" colspan="3">Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension</td> </tr> <tr> <td>N3</td> <td colspan="3">Metastasis in a lymph node, more than 6 cm in greatest dimension</td> </tr> <tr> <td class="subtitle1_single" colspan="4">Distant metastasis (M)</td> </tr> <tr> <td>M0</td> <td colspan="3">No distant metastases</td> </tr> <tr> <td>MI</td> <td colspan="3">Distant metastases</td> </tr> <tr> <td class="subtitle1_single" colspan="4">Anatomic stage/prognostic groups<sup>¶</sup></td> </tr> <tr> <td>Stage 0</td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage I</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage II</td> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan="4">Stage III</td> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T1</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T2</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N1</td> <td>M0</td> </tr> <tr> <td rowspan="6">Stage IV</td> <td>T1</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T2</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>N3</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>Any N</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class="graphic_lgnd">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class="graphic_footnotes">cSCC: cutaneous squamous cell carcinoma.<br/>* Excludes cSCC of the eyelid.<br/>¶ Patients with primary cSCC or other cutaneous carcinomas with no evidence (clinical, radiologic, or pathologic) of regional or distant metastases are divided into two stages: Stage I for tumors measuring ≤2 cm in size and Stage II for those that are greater than 2 cm in size. In instances where there is clinical concern for extension of tumor into bone and radiologic evaluation has been performed (and is negative), these data may be included to support the Stage I versus II designation. Tumors that are ≤2 cm in size can be upstaged to Stage II if they contain two or more high-risk features. Stage III patients are those with (1) clinical, histologic, or radiologic evidence of one solitary node measuring ≤3 cm in size or (2) tumor extension into bone: maxilla, mandible, orbit, or temporal bone. Stage IV patients are those with (1) tumor with direct or perineural invasion of skull base or axial skeleton, (2) ≥2 lymph nodes or (3) single or multiple lymph nodes measuring &gt;3 cm in size or (4) distant metastasis.</div><div class="graphic_reference">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id="graphicVersion">Graphic 78140 Version 17.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
